The rates of grade ≥ 3 AEs in patients receiving intermittent dosing were 15.0% for thrombocytopenia, 5.0% for neutropenia, and 0% for anemia, versus 36.2%, 20.3%, and 21.7%, respectively, in patients that received continuous dosing.51 While intermittent dosing may have helped reduce the occurrence of hematologic toxicities, baseline hematologic abnormalities may ultimately be a contraindication to therapy with MDM2 antagonists. The gene discussed is MDM2; the disease is Thrombocytopenia.